Survival Trends in Sorafenib for Advanced Hepatocellular Carcinoma: A Reconstructed Individual Patient Data Meta-analysis of Randomized Trials

Survival Trends in Sorafenib for Advanced Hepatocellular Carcinoma: A Reconstructed Individual Patient Data Meta-analysis of Randomized Trials

Background: Emerging data suggest that outcomes for advanced hepatocellular carcinoma (HCC) treated with sorafenib may have improved over time. We aimed to provide robust, time-to-event estimates of survival outcomes for sorafenib in advanced HCC. Summary: In this systematic review and individual...

Full description

Bibliographic Details
Main Authors:	Darren Jun Hao Tan, Ansel Shao Pin Tang, Wen Hui Lim, Cheng Han Ng, Benjamin Nah, Clarissa Fu, Jieling Xiao, Benjamin Koh, Phoebe Wen Lin Tay, Eunice X Tan, Margaret Teng, Nicholas Syn, Mark D Muthiah, Nobuharu Tamaki, Sung Won Lee, Beom Kyung Kim, Thomas Yau, Arndt Vogel, Rohit Loomba, Daniel Q. Huang
Format:	Article
Language:	English
Published:	Karger Publishers 2023-03-01
Series:	Liver Cancer
Online Access:	https://www.karger.com/Article/FullText/529824

Similar Items

Risk of hepatocellular carcinoma with tenofovir vs entecavir treatment for chronic hepatitis B virus: a reconstructed individual patient data meta-analysis
by: Tan, Darren Jun Hao, et al.
Published: (2023)

A qualitative systematic review of anonymous/unspecified living kidney and liver donors' perspectives
by: Lim, Wen Hui, et al.
Published: (2023)

A qualitative systematic review of anonymous/unspecified living kidney and liver donors' perspectives.
by: Wen Hui Lim, et al.
Published: (2022-01-01)

A poor perspective of self weight significantly increases adverse outcomes in non-alcoholic fatty liver disease (NAFLD)
by: Clarissa Elysia Fu, et al.
Published: (2022-09-01)

Prognostic utility of magnetic resonance elastography and MEFIB index in predicting liver-related outcomes and mortality in individuals at risk of and with nonalcoholic fatty liver disease
by: Veeral Ajmera, et al.
Published: (2022-04-01)

Depression in non-alcoholic fatty liver disease is associated with an increased risk of complications and mortality
by: Cheng Han Ng, et al.
Published: (2022-10-01)

Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis
by: Tan, Darren Jun Hao, et al.
Published: (2022)

Type 2 diabetes mellitus in metabolic-associated fatty liver disease vs. type 2 diabetes mellitus non-alcoholic fatty liver disease: a longitudinal cohort analysis
by: Mark Muthiah, et al.
Published: (2023-01-01)

Impact of pre-sarcopenia in sorafenib treatment for advanced hepatocellular carcinoma.
by: Hitomi Takada, et al.
Published: (2018-01-01)

Non-alcoholic fatty liver disease increases risk of carotid atherosclerosis and ischemic stroke: An updated meta-analysis with 135,602 individuals
by: Ansel Shao Pin Tang, et al.
Published: (2022-07-01)

Efficacy of sorafenib monotherapy versus sorafenib-based loco-regional treatments in advanced hepatocellular carcinoma.
by: Sangheun Lee, et al.
Published: (2013-01-01)

An Epidemiological Meta-Analysis on the Worldwide Prevalence, Resistance, and Outcomes of Spontaneous Bacterial Peritonitis in Cirrhosis
by: Phoebe Wen Lin Tay, et al.
Published: (2021-08-01)

Safety and tolerability of obeticholic acid in chronic liver disease: a pooled analysis of 1878 individuals
by: Cheng Han Ng, et al.
Published: (2023-03-01)

Evaluation of Liver Fibrosis and Inflammation Using Ultrasound Elastography
by: Nobuharu Tamaki, MD
Published: (2020-12-01)

Loss of lncRNA LINC01056 leads to sorafenib resistance in HCC
by: Yau-Tuen Chan, et al.
Published: (2024-04-01)

Pharmacokinetic Interaction between Sorafenib and Atorvastatin, and Sorafenib and Metformin in Rats
by: Agnieszka Karbownik, et al.
Published: (2020-06-01)

Diagnostic accuracy of two-dimensional shear wave elastography and transient elastography in nonalcoholic fatty liver disease
by: Suzanne R. Sharpton, et al.
Published: (2021-10-01)

Clinical usefulness of geriatric assessment in elderly patients with unresectable hepatocellular carcinoma receiving sorafenib or lenvatinib therapy
by: Shuhei Sekiguchi, et al.
Published: (2022-11-01)

The Development of Lipid-Based Sorafenib Granules to Enhance the Oral Absorption of Sorafenib
by: Jaylen C. Mans, et al.
Published: (2023-11-01)

Trial watch: immunotherapeutic strategies on the horizon for hepatocellular carcinoma
by: Benjamin Koh, et al.
Published: (2023-12-01)

Roles and Mechanisms of Ferroptosis in Sorafenib Resistance for Hepatocellular Carcinoma
by: Liu R, et al.
Published: (2024-12-01)

The Enhanced metastatic potential of hepatocellular carcinoma (HCC) cells with sorafenib resistance.
by: Ariel Ka-Man Chow, et al.
Published: (2013-01-01)

Population Pharmacokinetic Modelling and Simulation to Determine the Optimal Dose of Nanoparticulated Sorafenib to the Reference Sorafenib
by: Ki-Young Huh, et al.
Published: (2021-04-01)

Multicenter phase II study of sequential radioembolization-sorafenib therapy for inoperable hepatocellular carcinoma.
by: Pierce K H Chow, et al.
Published: (2014-01-01)

Global Prevalence, Risk Factors, and Outcomes of Depression After Liver Transplant: A Systematic Review and Meta-analysis
by: Wen Hui Lim, et al.
Published: (2022-01-01)

Sorafenib as an Inhibitor of RUVBL2
by: Nardin Nano, et al.
Published: (2020-04-01)

Effectiveness of Sorafenib in Hepatic Hemangioma
by: Prateek Tiwari, et al.
Published: (2017-05-01)

Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic Review.
by: James Mattina, et al.
Published: (2017-02-01)

Finding Harmony between Science and Art in Pediatric Cardiology: Acknowledging When Being “Objective” May Not Truly Be Objective
by: Rohit S. Loomba
Published: (2016-11-01)

Arterial desaturation due to pulmonary arteriovenous malformations after the Kawashima Operation
by: Rohit S Loomba
Published: (2016-01-01)

Natural History of Asymptomatic and Unrepaired Vascular Rings: Is Watchful Waiting a Viable Option? A New Case and Review of Previously Reported Cases
by: Rohit S. Loomba
Published: (2016-12-01)

Ramucirumab combination with sorafenib enhances the inhibitory effect of sorafenib on HepG2 cancer cells
by: Amna Mohamed Taha, et al.
Published: (2022-10-01)

Camrelizumab Plus Sorafenib Versus Sorafenib Monotherapy for Advanced Hepatocellular Carcinoma: A Retrospective Analysis
by: Qinqin Liu, et al.
Published: (2021-10-01)

Sorafenib plus hepatic arterial infusion chemotherapy with oxaliplatin versus sorafenib alone for advanced hepatocellular carcinoma
by: Yang Zhao, et al.
Published: (2019-05-01)

Phase II trial of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma after disease progression on sorafenib
by: Imane El Dika, et al.
Published: (2020-10-01)

Tislelizumab vs sorafenib in first-line treatment of unresectable hepatocellular carcinoma: impact on health-related quality of life in RATIONALE-301 study
by: Richard S. Finn, et al.
Published: (2024-02-01)

Clinical course, immunogenicity, and efficacy of BNT162b2 mRNA vaccination against SARS-CoV-2 infection in liver transplant recipients
by: Tan, Eunice X., et al.
Published: (2024)

Antiglioma Potential of Coumarins Combined with Sorafenib
by: Joanna Sumorek-Wiadro, et al.
Published: (2020-11-01)

Influence of Probenecid on the Pharmacokinetics and Pharmacodynamics of Sorafenib
by: Koen G. A. M. Hussaarts, et al.
Published: (2020-08-01)

Sorafenib-Induced Capillary Leak Syndrome
by: Hyunwoo Kwon, et al.
Published: (2023-10-01)